Quick Answer
Harmony Biosciences Holdings, Inc. reported Operating Income Loss of $208.47 million for the year ending 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +9.2% in Operating Income Loss from 2024 to 2025.
- This data is from Harmony Biosciences Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Harmony Biosciences Holdings, Inc.'s Operating Income Loss has grown by 242.9%.
- Historical annual values: Fiscal year 2025: $208.47 million | Fiscal year 2024: $190.83 million | Fiscal year 2023: $192.03 million | Fiscal year 2022: $120.19 million | Fiscal year 2021: $87.53 million | Fiscal year 2020: $16.99 million | Fiscal year 2019: -$145.90 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: